INOVIO Pharmaceuticals, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013; filed March 17, 2014. The company is a clinical-stage biotechnology business developing synthetic DNA vaccines and immune therapies, delivered using its CELLECTRA electroporation devices. It had no approved human products or product-sale revenue.
Financial results and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Total revenue | $13.47 million | $4.12 million |
| Operating expenses, net of asset-sale gains | $33.01 million | $27.61 million |
| Operating loss | $19.54 million | $23.49 million |
| Net loss attributable to Inovio | $66.03 million | $19.67 million |
| Basic and diluted loss per share | $0.36 | $0.14 |
| Cash and cash equivalents | $33.72 million | $5.65 million |
| Short-term investments | $18.91 million | $8.03 million |
| Working capital | $29.7 million | $7.6 million |
- Revenue rose 227%, principally due to the Roche agreement: Inovio recognized $9.18 million from Roche, or 68% of FY2013 revenue. NIAID contributed $2.09 million, or 16%.
- Research and development expense increased 19% to $21.37 million; general and administrative expense increased 27% to $13.64 million. Management attributed the increases to Roche-related work and fees, higher compensation, consulting, legal, rent and other costs.
- Operating loss narrowed by $3.95 million, but net loss widened substantially. The main driver was a $45.63 million adverse change in the fair value of common-stock warrant liabilities, largely reflecting the rise in the share price. This was a non-cash fair-value charge, not an operating expense.
- Cash used in operating activities was $15.38 million, down from $22.31 million. Financing activities provided $52.69 million, principally from equity offerings and warrant and option exercises. Investing activities used $9.24 million.
- At year-end, total liabilities were $35.38 million, including $19.54 million of current warrant liabilities. The filing reports no material long-term debt; contractual commitments were principally operating leases totaling $7.75 million.
- Accumulated deficit was $295.79 million. Management said cash, cash equivalents and short-term investments were expected to cover planned working-capital needs through the end of 2017, while noting continued reliance on outside financing thereafter.
Quarterly and year-over-year developments
- FY2013 revenue increased from FY2012’s low base, largely because of Roche’s upfront payment and associated license revenue. The $10 million Roche upfront payment was allocated among deliverables; the filing reports $9.1 million of Roche license revenue and $84,000 of research, development and manufacturing revenue in 2013, with $3.4 million deferred at year-end.
- In Q4 2013, revenue was $1.74 million and net loss attributable to Inovio was $15.45 million, or $0.07 per share. The quarter included a $6.05 million warrant fair-value loss. Q4 2012 revenue was $1.13 million and attributable net loss was $0.66 million; quarter-to-quarter net results were materially affected by warrant and affiliate-investment valuation changes.
- Roche revenue concentration is a significant change from 2012, when NIAID generated 69% of revenue and Roche generated none. Government and licensing revenue remain concentrated among a small number of counterparties.
Business, outlook, risks and unusual items
- Pipeline and plans: VGX-3100 was in a placebo-controlled Phase II study for HPV-related cervical dysplasia. The company planned to begin Phase I/IIa studies of INO-3112 for cervical and head-and-neck cancers in the first half of 2014, advance INO-1400 into clinical trials in 2014, and expected Roche-funded Phase I prostate-cancer work in the first half of 2014. Roche-funded HBV Phase I/IIa work was expected in early 2015. These are plans, not guarantees.
- Roche collaboration: Roche licensed INO-5150 and INO-1800 worldwide and agreed to fund ongoing development costs. Potential development, regulatory and commercial event payments could total up to $412.5 million, plus tiered royalties; payments depend on events and are not assured.
- Other funding: The NIAID HIV vaccine contract provides up to $25.3 million over seven years, subject to its terms and funding. The company was seeking grants or partners to advance influenza and malaria programs; the timing of malaria human studies depended on funding.
- Financing after year-end: On March 4, 2014, Inovio completed a public offering of 21.81 million shares at $2.90 per share, generating approximately $59.2 million net proceeds. This was subsequent to the balance-sheet date. The March 2013 financing, ATM sales and 2013 warrant and option exercises also increased cash but diluted shareholders.
- Key risks: The company has a long history of losses, no approved human products and uncertain clinical and regulatory outcomes. It faces significant future research, trial and commercialization costs; may need additional capital; relies on a few partners and government programs; and depends on third parties for manufacturing and clinical trials. Competition, intellectual-property challenges, reimbursement and product-liability risks are also disclosed.
- Unusual accounting and contingencies: Registered warrants were recorded as current liabilities and remeasured using a Black-Scholes model, creating substantial non-cash earnings volatility. The filing notes ownership-change restrictions may limit use of tax loss and credit carryforwards. It reports no material legal proceedings and no off-balance-sheet arrangements.
- Controls and audit: Management and the independent auditor concluded internal control over financial reporting was effective as of December 31, 2013. The auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Clinical-trial progress and results versus the company’s stated 2014–2015 timelines, especially for VGX-3100, INO-3112, INO-5150 and INO-1800.
- Roche’s actual development spending, achievement of payment milestones, and the conditions and scope of the potential $412.5 million in event-based payments and royalties.
- Cash use, current liquidity and financing needs against management’s runway estimate; separately account for the March 2014 offering proceeds and subsequent share issuance.
- Potential dilution from outstanding warrants, options and future equity financing, and the continuing effect of warrant fair-value accounting on reported net income or loss.
- Revenue concentration and continuity of Roche, NIAID and other grant or collaboration funding.
- Whether clinical, manufacturing, regulatory, patent, or funding setbacks alter pipeline plans or require additional spending.